â– LECTURE OVERVIEW: Neonatal Jaundice (hyperbilirubinemia) is a common clinical finding, classified chronologically into physiological and pathological profiles.
â– THE DYNAMIC SPLITS:
1. Physiological Jaundice (Normal/Benign):
- Pathogenesis: Caused by a transient, relative deficiency of hepatic UDP-glucuronosyltransferase (UGT) activity in a neonate with high red cell turnover.
- Timeline: Arises after the first 24 hours of life, peaking on days 3-5 before resolving.
2. Pathological Jaundice (Diseased):
- Pathogenesis: Driven by hemolysis (e.g., Rh/ABO incompatibility), biliary atresia, or sepsis.
- Timeline: Begins within the first 24 hours of life. Bilirubin levels rise quickly (>5 mg/dL/day or >15 mg/dL total).
â– PHARMACOKINETIC & PHARMACODYNAMIC ATTRIBUTES:
Absorption and steady-state kinetics display high variability based on plasma protein binding levels, tissue volume of distribution (Vd), and hepatic CYP450 microsomal enzymatic clearance indices.
â– PEDIATRIC CONTEXT & CONTINGENCIES:
Developing cohorts present with high body-water percentages and dynamic hepatic enzyme maturation pathways.
[HY-BOARD-1152]
🌟 Dynamic Clinical Key:
In pathological jaundice, high levels of unconjugated (indirect) bilirubin can cross the blood-brain barrier. Bilirubin deposits selectively in the basal ganglia, predisposing the neonate to acute bilirubin encephalopathy or permanent, devastating Kernicterus. Closely monitor serum plasma concentrations if drugs display a narrow therapeutic window to mitigate toxic peaks. Always utilize body-surface-area or weight-based dosing calculators for pediatric populations.